We also observed a trend toward a higher expression level of the five ICs in stage II cancers, particularly compared to stage III; this finding is different from previous reports showing an increased frequency of TILs expressing these ICs in advanced stages of CRC (for PD-1 [15]; for TIGIT [16]; and for Tim-3 [14,26,31]). This evidence concerns the gene PDCD1 and cancer.